TIOTROPIUM TRIAL # 205338

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 囊性纤维化是一种遗传性常染色体隐性遗传性疾病，它扰乱了呼吸道的离子运输，导致慢性感染、炎症和输卵管阻塞。需要新的药物来治疗肺梗阻，并为CF患者提供额外的好处。该方案是一项多中心、随机、双盲、剂量递增、安慰剂对照研究，用于治疗慢性阻塞性肺疾病的长效吸入型抗胆碱能支气管扩张剂噻托溴铵。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Cystic fibrosis (CF) is an inherited autosomal recessive disease that disrupts ion transport in the respiratory tract, leading to chronic infection, inflammation, and obstruction of the conducting airways. New medications are needed to treat pulmonary obstruction and provide additional benefits to CF patients. This protocol is a multi-center, randomized, double-blind, dose-escalation, placebo-controlled study of tiotropium bromide, a long-acting inhaled anticholinergic bronchodilator, in the treatment of CF lung disease.